A research team from China focused on the effects of the chemokine stromal cell-derived factor-1 receptor (CXCR4) antagonist AMD3100 on the intestinal epithelial barrier. They found that CXCR4 antagonist AMD3100 exerts therapeutic effects on experimental colitis by inhibiting colonic inflammation and enhancing epithelial barrier integrity.
Results 1 to 1 of 1
MEDiscuss • Medical News • A future strategy for the treatment of patients with ulcerative colitis
- June 24th, 2010 #1Bot
- Member since
- Jul 2007
- Posts
- 20,741
A future strategy for the treatment of patients with ulcerative colitis
QuoteRelated Posts
-
Road block as a new strategy for the treatment of Alzheimer's
By MedBot in forum Medical NewsReplies: 0Last Post: August 22nd, 2011, 03:07 PM -
Colitis patients diagnosed later in life tend to have better disease outcomes
By MedBot in forum Medical NewsReplies: 0Last Post: August 2nd, 2010, 11:30 PM -
Discovery may aid remission of ulcerative colitis
By MedBot in forum Medical NewsReplies: 0Last Post: June 15th, 2010, 12:52 AM -
Olive oil could guard against developing ulcerative colitis
By MedBot in forum Medical NewsReplies: 0Last Post: May 4th, 2010, 03:00 AM -
Genes linked to ulcerative colitis identified
By MedBot in forum Medical NewsReplies: 0Last Post: March 18th, 2010, 04:25 AM
Posting Permissions
The information provided on this site is meant to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
© 2007 - 2012 MEDiscuss | Powered by vBulletin® | Search Engine Optimization by vBSEO | vB skin by CompleteVB
All times are GMT. The time now is 09:47 PM.